News Shalov Stone Bonner & Rocco LLP Files Securities Fraud Class Action Against GPC Biotech AG Shalov Stone Bonner & Rocco LLP 08/13/2007

 

Shalov Stone Bonner & Rocco LLP has filed a securities fraud class action against GPC Biotech AG (NASDAQ:GPCB) ("GPC" or the "Company") and certain of its executive officers, on behalf of all persons and entities who purchased or otherwise acquired GPC securities between December 5, 2005, and July 24, 2007, inclusive (the "Class Period"). The class action lawsuit was filed in the United States District Court for the Southern District of New York.

According to the complaint, GPC and the other defendants violated the Securities Exchange Act of 1934. Specifically, the complaint alleges that, during the Class Period, the defendants made a series of materially false and misleading misrepresentations and omissions about the Company's operations, financial condition, and business prospects, including those concerning the prospects for FDA approval of GPC's leading drug candidate, Satraplatin (a treatment for advanced prostate cancer), thereby artificially inflating the price of the Company's securities during the Class Period.

For additional information about the lawsuit, please contact Thomas G. Ciarlone, Jr., at (212) 239-4340, or by e-mail: tciarlone@lawssb.com

Complaint
Certification